Clinical Validation of Heart Rate Apps: Mixed-Methods Evaluation Study
BackgroundPhotoplethysmography (PPG) is a proven way to measure heart rate (HR). This technology is already available in smartphones, which allows measuring HR only by using the smartphone. Given the widespread availability of smartphones, this creates a scalable way to enabl...
Main Authors: | , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
JMIR Publications
2017-08-01
|
Series: | JMIR mHealth and uHealth |
Online Access: | http://mhealth.jmir.org/2017/8/e129/ |
id |
doaj-afa6b83b595046a6bfd5b2df937b9603 |
---|---|
record_format |
Article |
spelling |
doaj-afa6b83b595046a6bfd5b2df937b96032021-05-03T01:40:55ZengJMIR PublicationsJMIR mHealth and uHealth2291-52222017-08-0158e12910.2196/mhealth.7254Clinical Validation of Heart Rate Apps: Mixed-Methods Evaluation StudyVandenberk, ThijsStans, JelleMortelmans, ChristopheVan Haelst, RuthVan Schelvergem, GertjanPelckmans, CarolineSmeets, Christophe JPLanssens, DorienDe Cannière, HélèneStorms, ValerieThijs, Inge MVaes, BertVandervoort, Pieter M BackgroundPhotoplethysmography (PPG) is a proven way to measure heart rate (HR). This technology is already available in smartphones, which allows measuring HR only by using the smartphone. Given the widespread availability of smartphones, this creates a scalable way to enable mobile HR monitoring. An essential precondition is that these technologies are as reliable and accurate as the current clinical (gold) standards. At this moment, there is no consensus on a gold standard method for the validation of HR apps. This results in different validation processes that do not always reflect the veracious outcome of comparison. ObjectiveThe aim of this paper was to investigate and describe the necessary elements in validating and comparing HR apps versus standard technology. MethodsThe FibriCheck (Qompium) app was used in two separate prospective nonrandomized studies. In the first study, the HR of the FibriCheck app was consecutively compared with 2 different Food and Drug Administration (FDA)-cleared HR devices: the Nonin oximeter and the AliveCor Mobile ECG. In the second study, a next step in validation was performed by comparing the beat-to-beat intervals of the FibriCheck app to a synchronized ECG recording. ResultsIn the first study, the HR (BPM, beats per minute) of 88 random subjects consecutively measured with the 3 devices showed a correlation coefficient of .834 between FibriCheck and Nonin, .88 between FibriCheck and AliveCor, and .897 between Nonin and AliveCor. A single way analysis of variance (ANOVA; P=.61 was executed to test the hypothesis that there were no significant differences between the HRs as measured by the 3 devices. In the second study, 20,298 (ms) R-R intervals (RRI)–peak-to-peak intervals (PPI) from 229 subjects were analyzed. This resulted in a positive correlation (rs=.993, root mean square deviation [RMSE]=23.04 ms, and normalized root mean square error [NRMSE]=0.012) between the PPI from FibriCheck and the RRI from the wearable ECG. There was no significant difference (P=.92) between these intervals. ConclusionsOur findings suggest that the most suitable method for the validation of an HR app is a simultaneous measurement of the HR by the smartphone app and an ECG system, compared on the basis of beat-to-beat analysis. This approach could lead to more correct assessments of the accuracy of HR apps.http://mhealth.jmir.org/2017/8/e129/ |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Vandenberk, Thijs Stans, Jelle Mortelmans, Christophe Van Haelst, Ruth Van Schelvergem, Gertjan Pelckmans, Caroline Smeets, Christophe JP Lanssens, Dorien De Cannière, Hélène Storms, Valerie Thijs, Inge M Vaes, Bert Vandervoort, Pieter M |
spellingShingle |
Vandenberk, Thijs Stans, Jelle Mortelmans, Christophe Van Haelst, Ruth Van Schelvergem, Gertjan Pelckmans, Caroline Smeets, Christophe JP Lanssens, Dorien De Cannière, Hélène Storms, Valerie Thijs, Inge M Vaes, Bert Vandervoort, Pieter M Clinical Validation of Heart Rate Apps: Mixed-Methods Evaluation Study JMIR mHealth and uHealth |
author_facet |
Vandenberk, Thijs Stans, Jelle Mortelmans, Christophe Van Haelst, Ruth Van Schelvergem, Gertjan Pelckmans, Caroline Smeets, Christophe JP Lanssens, Dorien De Cannière, Hélène Storms, Valerie Thijs, Inge M Vaes, Bert Vandervoort, Pieter M |
author_sort |
Vandenberk, Thijs |
title |
Clinical Validation of Heart Rate Apps: Mixed-Methods Evaluation Study |
title_short |
Clinical Validation of Heart Rate Apps: Mixed-Methods Evaluation Study |
title_full |
Clinical Validation of Heart Rate Apps: Mixed-Methods Evaluation Study |
title_fullStr |
Clinical Validation of Heart Rate Apps: Mixed-Methods Evaluation Study |
title_full_unstemmed |
Clinical Validation of Heart Rate Apps: Mixed-Methods Evaluation Study |
title_sort |
clinical validation of heart rate apps: mixed-methods evaluation study |
publisher |
JMIR Publications |
series |
JMIR mHealth and uHealth |
issn |
2291-5222 |
publishDate |
2017-08-01 |
description |
BackgroundPhotoplethysmography (PPG) is a proven way to measure heart rate (HR). This technology is already available in smartphones, which allows measuring HR only by using the smartphone. Given the widespread availability of smartphones, this creates a scalable way to enable mobile HR monitoring. An essential precondition is that these technologies are as reliable and accurate as the current clinical (gold) standards. At this moment, there is no consensus on a gold standard method for the validation of HR apps. This results in different validation processes that do not always reflect the veracious outcome of comparison.
ObjectiveThe aim of this paper was to investigate and describe the necessary elements in validating and comparing HR apps versus standard technology.
MethodsThe FibriCheck (Qompium) app was used in two separate prospective nonrandomized studies. In the first study, the HR of the FibriCheck app was consecutively compared with 2 different Food and Drug Administration (FDA)-cleared HR devices: the Nonin oximeter and the AliveCor Mobile ECG. In the second study, a next step in validation was performed by comparing the beat-to-beat intervals of the FibriCheck app to a synchronized ECG recording.
ResultsIn the first study, the HR (BPM, beats per minute) of 88 random subjects consecutively measured with the 3 devices showed a correlation coefficient of .834 between FibriCheck and Nonin, .88 between FibriCheck and AliveCor, and .897 between Nonin and AliveCor. A single way analysis of variance (ANOVA; P=.61 was executed to test the hypothesis that there were no significant differences between the HRs as measured by the 3 devices. In the second study, 20,298 (ms) R-R intervals (RRI)–peak-to-peak intervals (PPI) from 229 subjects were analyzed. This resulted in a positive correlation (rs=.993, root mean square deviation [RMSE]=23.04 ms, and normalized root mean square error [NRMSE]=0.012) between the PPI from FibriCheck and the RRI from the wearable ECG. There was no significant difference (P=.92) between these intervals.
ConclusionsOur findings suggest that the most suitable method for the validation of an HR app is a simultaneous measurement of the HR by the smartphone app and an ECG system, compared on the basis of beat-to-beat analysis. This approach could lead to more correct assessments of the accuracy of HR apps. |
url |
http://mhealth.jmir.org/2017/8/e129/ |
work_keys_str_mv |
AT vandenberkthijs clinicalvalidationofheartrateappsmixedmethodsevaluationstudy AT stansjelle clinicalvalidationofheartrateappsmixedmethodsevaluationstudy AT mortelmanschristophe clinicalvalidationofheartrateappsmixedmethodsevaluationstudy AT vanhaelstruth clinicalvalidationofheartrateappsmixedmethodsevaluationstudy AT vanschelvergemgertjan clinicalvalidationofheartrateappsmixedmethodsevaluationstudy AT pelckmanscaroline clinicalvalidationofheartrateappsmixedmethodsevaluationstudy AT smeetschristophejp clinicalvalidationofheartrateappsmixedmethodsevaluationstudy AT lanssensdorien clinicalvalidationofheartrateappsmixedmethodsevaluationstudy AT decannierehelene clinicalvalidationofheartrateappsmixedmethodsevaluationstudy AT stormsvalerie clinicalvalidationofheartrateappsmixedmethodsevaluationstudy AT thijsingem clinicalvalidationofheartrateappsmixedmethodsevaluationstudy AT vaesbert clinicalvalidationofheartrateappsmixedmethodsevaluationstudy AT vandervoortpieterm clinicalvalidationofheartrateappsmixedmethodsevaluationstudy |
_version_ |
1721485867390861312 |